Travel and Home Insurance Under Scrutiny: Consumer Complaints, Cyber Risks, and Health Disclosure Challenges

Consumer group Which? has submitted a super-complaint to the UK regulator, highlighting widespread failings in home and travel insurance, including poor claims handling, problematic sales practices, and weak enforcement of existing rules. Research shows some consumers face extreme price hikes or outright refusals, especially those with pre-existing conditions, creating a major imbalance of power between insurers and policyholders. Martin Lewis and others have welcomed the complaint, calling for stronger regulation and fair treatment. Which? argues that the Financial Conduct Authority (FCA) has so far done little to address persistent issues, and urgent action is needed to protect consumers.
Nearly half of UK consumers (45.7%) would consider paying more for travel insurance that automatically pays out for delays or cancellations, according to GlobalData. The recent cyber attack on airports including Heathrow, Dublin, and Brussels caused widespread flight disruptions, highlighting the value of parametric travel insurance for quick payouts. The incident also underscores the rising threat of cyber attacks, with over half of brokers seeing cyber insurance as a high-growth product. Insurers are encouraged to promote parametric and cyber coverage as essential protections for travellers and businesses in an increasingly digital and risk-prone environment.
New research shows that a quarter of UK adults are unsure whether GLP-1 weight-loss drugs like Mounjaro, Wegovy, and Ozempic count as pre-existing conditions for travel or health insurance. With 6% of the population already using these medications and demand expected to surge, this uncertainty could lead to claim disputes and coverage gaps. Many people inconsistently classify treatments, for example labeling Botox as cosmetic even when used medically. Consumer Intelligence warns insurers face a critical challenge in underwriting and may need new categories for preventative health treatments. Clearer guidance and insurance question wording are essential to prevent non-disclosure and related disputes.